Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Ngian, Gene Siew ^a   Stevens, Wendy ^b   Prior, David ^b   Gabbay, Eli ^c   Roddy, Janet ^c   Tran, Ai ^c   Minson, Robert ^d   Hill, Catherine ^e   Chow, Ken ^f   Sahhar, Joanne ^g   Proudman, Susanna ^f   Nikpour, Mandana ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

Author keywords

Connective tissue disease; mortality; prognosis

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONNECTIVE TISSUE DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; PERICARDIAL EFFUSION; PROGNOSIS; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; AUSTRALIA; BLOOD PRESSURE; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; CONNECTIVE TISSUE DISEASES; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; WALKING;

AGED; AUSTRALIA; BLOOD PRESSURE; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; WALKING; WARFARIN;

EID: 84867013258     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4051     Document Type: Article

References (34)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944. 10.1136/ard.2006.066068, 1955114, 17329309.
2. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S78-84. 10.1016/j.jacc.2009.04.017, 19555861.
3. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403. 2642921, 19155250.
4. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926-932. 10.1136/hrt.2005.069484, 1860719, 16339813.
5. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-1394. 10.1378/chest.10-0260, 20507945.
6. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S55-66. 10.1016/j.jacc.2009.04.011, 19555859.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
10. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989, 16:328-334.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
12. Rich S. Primary Pulmonary Hypertension: Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998, Geneva: World Health Organization.
13. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
14. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254. 10.1164/rccm.200706-877OC, 18369202.
15. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983, 39:499-503. 10.2307/2531021, 6354290.
16. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-54. 10.1016/j.jacc.2009.04.012, 19555858.
17. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
18. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med 2010, 104:1588-1607. 10.1016/j.rmed.2010.08.003, 20810261.
19. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487-492.
20. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302. 10.1056/NEJM199602013340504, 8532025.
21. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
22. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903. 10.1056/NEJMoa012212, 11907289.
23. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329. 10.1056/NEJMoa020204, 12151469.
24. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157. 10.1056/NEJMoa050010, 16291984.
25. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009, 36:330-336. 10.3899/jrheum.080447, 19208563.
26. Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS, Murugappan M, Chakinali MM, Palevsky HI, Gallop R. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 2009, 84:586-592. 2704130, 19567712.
27. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wigley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54:3043-3050. 10.1002/art.22069, 16947776.
28. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, Schwartz T, Koch G, Clayton LM, Jobsis MM, Crow JW, Long W. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002, 39:1214-1219. 10.1016/S0735-1097(02)01744-8, 11923049.
29. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol 2011, 38:462-469. 10.3899/jrheum.100632, 21159827.
30. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006, 130:545-552. 10.1378/chest.130.2.545, 16899857.
31. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006, 28:999-1004. 10.1183/09031936.06.00015206, 17074918.
32. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, Seary ME, Hawker GA, Feldman BM. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012, 39:276-285. 10.3899/jrheum.110765, 22247353.
33. Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther 2008, 28:412-421. 10.1111/j.1365-2036.2008.03739.x, 18498445.
34. Keogh A, Strange G, Kotlyar E, Williams T, Kilpatrick D, Macdonald P, Brown K, Pidoux A, Kermeen F, Steele P, Dalton B, Gabbay E. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J 2011, 41:235-244. 10.1111/j.1445-5994.2010.02403.x, 21118410.